Aerie Pharma (AERI) PT Raised to $70 at Aegis Capital Following Phase III Trial
Tweet Send to a Friend
Aegis Capital raised its price target on Aerie Pharma (NASDAQ: AERI) to $70.00 (from $63.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
